PortalPublikationenThe IL-1β, IL-6, and TNF cytokine triad is associated with p...

The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19

Standard

The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. / Schultheiß, Christoph; Willscher, Edith; Paschold, Lisa; Gottschick, Cornelia; Klee, Bianca; Henkes, Svenja-Sibylla; Bosurgi, Lidia; Dutzmann, Jochen; Sedding, Daniel; Frese, Thomas; Girndt, Matthias; Höll, Jessica; Gekle, Michael; Mikolajczyk, Rafael; Binder, Mascha.

in: CELL REP MED, Jahrgang 3, Nr. 6, 100663, 21.06.2022, S. 100663.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schultheiß, C, Willscher, E, Paschold, L, Gottschick, C, Klee, B, Henkes, S-S, Bosurgi, L, Dutzmann, J, Sedding, D, Frese, T, Girndt, M, Höll, J, Gekle, M, Mikolajczyk, R & Binder, M 2022, 'The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19', CELL REP MED, Jg. 3, Nr. 6, 100663, S. 100663. https://doi.org/10.1016/j.xcrm.2022.100663

APA

Schultheiß, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Henkes, S-S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., Girndt, M., Höll, J., Gekle, M., Mikolajczyk, R., & Binder, M. (2022). The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. CELL REP MED, 3(6), 100663. [100663]. https://doi.org/10.1016/j.xcrm.2022.100663

Vancouver

Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes S-S et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. CELL REP MED. 2022 Jun 21;3(6):100663. 100663. https://doi.org/10.1016/j.xcrm.2022.100663

Bibtex

@article{debbd26375694fe89d2bf86824992559,
title = "The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19",
abstract = "Post-acute sequelae of COVID-19 (PASC) is emerging as global problem with unknown molecular drivers. Using a digital epidemiology approach, we recruited 8,077 individuals to the cohort study for digital health research in Germany (DigiHero) to respond to a basic questionnaire followed by a PASC-focused survey and blood sampling. We report the first 318 participants, the majority thereof after mild infections. Of those, 67.8% report PASC, predominantly consisting of fatigue, dyspnea, and concentration deficit, which persists in 60% over the mean 8-month follow-up period and resolves independently of post-infection vaccination. PASC is not associated with autoantibodies, but with elevated IL-1β, IL-6, and TNF plasma levels, which we confirm in a validation cohort with 333 additional participants and a longer time from infection of 10 months. Blood profiling and single-cell data from early infection suggest the induction of these cytokines in COVID-19 lung pro-inflammatory macrophages creating a self-sustaining feedback loop.",
author = "Christoph Schulthei{\ss} and Edith Willscher and Lisa Paschold and Cornelia Gottschick and Bianca Klee and Svenja-Sibylla Henkes and Lidia Bosurgi and Jochen Dutzmann and Daniel Sedding and Thomas Frese and Matthias Girndt and Jessica H{\"o}ll and Michael Gekle and Rafael Mikolajczyk and Mascha Binder",
year = "2022",
month = jun,
day = "21",
doi = "10.1016/j.xcrm.2022.100663",
language = "English",
volume = "3",
pages = "100663",
journal = "CELL REP MED",
issn = "2666-3791",
publisher = "Cell Press",
number = "6",

}

RIS

TY - JOUR

T1 - The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19

AU - Schultheiß, Christoph

AU - Willscher, Edith

AU - Paschold, Lisa

AU - Gottschick, Cornelia

AU - Klee, Bianca

AU - Henkes, Svenja-Sibylla

AU - Bosurgi, Lidia

AU - Dutzmann, Jochen

AU - Sedding, Daniel

AU - Frese, Thomas

AU - Girndt, Matthias

AU - Höll, Jessica

AU - Gekle, Michael

AU - Mikolajczyk, Rafael

AU - Binder, Mascha

PY - 2022/6/21

Y1 - 2022/6/21

N2 - Post-acute sequelae of COVID-19 (PASC) is emerging as global problem with unknown molecular drivers. Using a digital epidemiology approach, we recruited 8,077 individuals to the cohort study for digital health research in Germany (DigiHero) to respond to a basic questionnaire followed by a PASC-focused survey and blood sampling. We report the first 318 participants, the majority thereof after mild infections. Of those, 67.8% report PASC, predominantly consisting of fatigue, dyspnea, and concentration deficit, which persists in 60% over the mean 8-month follow-up period and resolves independently of post-infection vaccination. PASC is not associated with autoantibodies, but with elevated IL-1β, IL-6, and TNF plasma levels, which we confirm in a validation cohort with 333 additional participants and a longer time from infection of 10 months. Blood profiling and single-cell data from early infection suggest the induction of these cytokines in COVID-19 lung pro-inflammatory macrophages creating a self-sustaining feedback loop.

AB - Post-acute sequelae of COVID-19 (PASC) is emerging as global problem with unknown molecular drivers. Using a digital epidemiology approach, we recruited 8,077 individuals to the cohort study for digital health research in Germany (DigiHero) to respond to a basic questionnaire followed by a PASC-focused survey and blood sampling. We report the first 318 participants, the majority thereof after mild infections. Of those, 67.8% report PASC, predominantly consisting of fatigue, dyspnea, and concentration deficit, which persists in 60% over the mean 8-month follow-up period and resolves independently of post-infection vaccination. PASC is not associated with autoantibodies, but with elevated IL-1β, IL-6, and TNF plasma levels, which we confirm in a validation cohort with 333 additional participants and a longer time from infection of 10 months. Blood profiling and single-cell data from early infection suggest the induction of these cytokines in COVID-19 lung pro-inflammatory macrophages creating a self-sustaining feedback loop.

U2 - 10.1016/j.xcrm.2022.100663

DO - 10.1016/j.xcrm.2022.100663

M3 - SCORING: Journal article

C2 - 35732153

VL - 3

SP - 100663

JO - CELL REP MED

JF - CELL REP MED

SN - 2666-3791

IS - 6

M1 - 100663

ER -